Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma

Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death‐1 inhibitors: A review of the literature

“…Recommended doses are 3 mg for kilograms of weight every 3 weeks as intravenous (iv) infusion for a period of 30 minutes. Among the different PD-1 inhibitors, the number of patients treated is the widest, about 28 reported in the literature (Assam et al, 2016;Borradori et al, 2016;Chang et al, 2016;Degache et al, 2018;Deinlein et al, 2017;Ferrarotto, 2017;Lipson et al, 2016;Ravulapati et al, 2017;Stevenson et al, 2017;Tran et al, 2017;Winkler et al, 2017;Zalaudek et al, 2019), excluding the ongoing trials in Phase I and II (Licitra et al, 2017;Kudchadkar et al, 2018;Maubec et al, 2019). Although the larger number of reported cases, responses data are not enough and in addition with short period of follow-up.…”

Anti‐PD1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature

“…Batches of innovator adalimumab produced from 2001 to 2013 contained between 83% and 89% of cleaved C-terminal lysine residues. 5 However, the quantity of lysine residues varied within the same calendar year and from year to year. In 2004 and 2005, the quantity of C-terminal lysine residues ranged from 86% to 88% and from 87% to 89%, respectively.…”

“…In 2004 and 2005, the quantity of C-terminal lysine residues ranged from 86% to 88% and from 87% to 89%, respectively. 5 Similar to adalimumab, batches of innovator etanercept vary within and between each process revision from 1998 to 2015. The following mean and median ranges compare standard (Process A) to process revisions (Process B, C, D) based on several physiochemical characteristics: quantity of aggregated and misfolded species (18-20%, 15%, 12-14%, 15-16%), purity/impurity (30-34 ppm, 10-12 ppm, 4-5 ppm, 5-6 ppm), binding to TNF [107-108 binding units (BU), 111-113 BU, 115-117 BU, 111-113 BU] and potency to inhibit TNF-based apoptosis (1.5-1.6 U/mg, 1.7-1.8 U/mg, 1.7-1.8 U/mg, 1.7-1.75 U/mg) across all batches, respectively.…”

“…Five patients were in CR, 8 were in PR, and 3 were stable. [3][4][5][6] More recently, the results of a phase 2 study assessing cemiplimab (anti-PD1) in 59 patients with advanced CSCC were published with a response rate of 47%. 7 Regarding MCC, in 2016, Nghiem et al have reported 25 patients treated with pembrolizumab with an objective response rate (ORR) of 56% with viro-positive and viro-negative MCC with low and high mutational loads, respectively.…”

Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma

“…In a preclinical mouse model, PD-1-PDL-1 activation contributed to the development of cSCC [6]. Moreover, the efficacy of anti-PD-1 mAb in patients with cSCC has been reported recently in a few case series [7][8][9][10][11][12][13][14][15][16][17] and in a Phase 1-2 trial with cemiplimab [18]. Herein, we report for the first time two complete responses (CR), allowing treatment discontinuation without recurrence to date, in a series of four patients with advanced cSCC treated with pembrolizumab and concurrent hypofractionated radiotherapy.…”